SJEPD031078_D2.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- age_years
- 0.84
- e1_e2
- E2
- umap1_2d
- -7.022612169
- umap2_2d
- 1.414027617
- umap1_3d
- 0.05956586
- umap2_3d
- 4.679261683
- umap3_3d
- 0.160307531
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.510
- PROTEIN_SECRETION+0.450
- FATTY_ACID_METABOLISM+0.290
- PEROXISOME+0.290
- ADIPOGENESIS+0.270
- DNA_REPAIR+0.250
- BILE_ACID_METABOLISM+0.230
- MITOTIC_SPINDLE+0.210
- UV_RESPONSE_DN+0.200
- MYC_TARGETS_V1+0.180
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.540
- INFLAMMATORY_RESPONSE-0.470
- IL6_JAK_STAT3_SIGNALING-0.410
- ALLOGRAFT_REJECTION-0.380
- HEDGEHOG_SIGNALING-0.380
- CHOLESTEROL_HOMEOSTASIS-0.370
- APICAL_SURFACE-0.360
- HYPOXIA-0.360
- INTERFERON_ALPHA_RESPONSE-0.360
- MYOGENESIS-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030580_D1.RNA-Seq | EPN | EPN Tumor | 0.899 |
| 2 | BS_3F4FQJMR | Supratentorial Ependymoma | — | 0.891 |
| 3 | BS_3F4FQJMR | EPN | Supratentorial EPN | 0.877 |
| 4 | 20040104.LumB | — | B | 0.875 |
| 5 | 877f3bcc-97ea-4b0e-9f61-98a9eaedd952 | — | — | 0.871 |
| 6 | BS_J8G4SH4Z | Med | Medulloblastoma | 0.868 |
| 7 | SRR10900558 | — | — | 0.868 |
| 8 | BS_KYF0Q0E7 | Med | Medulloblastoma | 0.865 |
| 9 | SJEPD030948_D1.RNA-Seq | EPN | EPN Tumor | 0.863 |
| 10 | b320695d.4881.4d6a.b284.847cd248be24 | — | cohortA1 | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| PEROXISOME | 0.290 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.070 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.070 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |